SynthesisFrontiers in cellular and infection microbiology2025
Comparison with healthy controls: meta-analysis of changes in intestinal flora in Chinese patients with irritable bowel syndrome.
Synthesis in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The characteristics of the gut microbiota in Chinese patients with irritable bowel syndrome (IBS) and their association with the disease remain unclear. Although current studies have revealed some changes in the gut microbiota of IBS patients, these changes vary across different studies and no consistent conclusions have been reached. Additionally, geographical differences may lead to unique microbial characteristics in IBS patients, which could serve as potential diagnostic tools or therapeutic targets. We hypothesize that the gut microbiota of Chinese IBS patients exhibits unique compositional and functional characteristics that differ significantly from those of healthy individuals. Aim: To investigate differential characteristics of gut microbiota in Chinese patients with IBS compared to healthy controls (HC). Methods: We conducted a comprehensive search in PubMed, Web of Science, Embase, and China National Knowledge Infrastructure (CNKI) databases from their inception to May 2025. The search strategy was built around key concepts of IBS, gut microbiota, and China, combining subject headings (e.g., MeSH terms) and free-text keywords. The search was performed in line with the PRISMA guidelines. Studies were included if they were case-control studies comparing gut microbiota between IBS patients and all participants were Chinese, IBS diagnosis adhered to internationally recognized Rome criteria, HCs were free from gastrointestinal diseases, and sufficient data were provided for meta-analysis. Exclusion criteria encompassed non-case-control designs, studies involving non-Chinese populations or mixed control groups, unavailable or insufficient data, and studies of low methodological quality (NOS score < 5). Study selection was carried out by two researchers independently. Data were extracted and quality assessed using the Newcastle-Ottawa Scale (NOS). The quality assessment was independently conducted by two researchers, and any discrepancies were resolved with the assistance of a third researcher. Data were analyzed using RevMan 5.4 software, with standardized mean differences (SMD) and 95% confidence intervals (CIs) calculated. The I Results: This meta-analysis of 12 studies (766 IBS patients, 351 HC) revealed that Chinese IBS patients exhibited significantly higher abundance of Conclusion: This meta-analysis reveals gut microbiota imbalances in Chinese IBS patients: significantly increased
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.